Gyre Total Assets vs Total Current Liabilities Analysis
| GYRE Stock | 11.63 0.34 3.01% |
Gyre Therapeutics financial indicator trend analysis is much more than just examining Gyre Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gyre Therapeutics is a good investment. Please check the relationship between Gyre Therapeutics Total Assets and its Total Current Liabilities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.
Total Assets vs Total Current Liabilities
Total Assets vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gyre Therapeutics Total Assets account and Total Current Liabilities. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Gyre Therapeutics' Total Assets and Total Current Liabilities is 0.54. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Gyre Therapeutics, assuming nothing else is changed. The correlation between historical values of Gyre Therapeutics' Total Assets and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Gyre Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Assets i.e., Gyre Therapeutics' Total Assets and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.54 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Total Assets
Total assets refers to the total amount of Gyre Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Gyre Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Gyre Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Gyre Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Gyre Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gyre Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.The current year's Enterprise Value is expected to grow to about 2.2 B, whereas Selling General Administrative is forecasted to decline to about 13.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 290K | 1.1M | 1.1M | 740.7K | Cost Of Revenue | 7.4M | 798K | 4.6M | 7.7M |
Gyre Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Gyre Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gyre Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 98.6M | 94.8M | 55.7M | 28.4M | 116.5M | 116.9M | |
| Total Stockholder Equity | 68.3M | 76.1M | 41.1M | (21.7M) | (15.8M) | (15.0M) | |
| Retained Earnings | (258.5M) | (314.8M) | (402.7M) | (410.9M) | (85.5M) | (89.8M) | |
| Common Stock Shares Outstanding | 12.0M | 19.2M | 30.6M | 75.7M | 65.8M | 69.1M | |
| Liabilities And Stockholders Equity | 98.6M | 94.8M | 55.7M | 28.4M | 116.5M | 116.9M | |
| Other Stockholder Equity | 326.8M | 390.8M | 443.8M | 32.8M | 3.7M | 3.5M | |
| Net Debt | (13.6M) | (28.7M) | (42.0M) | (21.6M) | (33.1M) | (34.8M) | |
| Non Current Liabilities Total | 1.3M | 981K | 408K | 33.3M | 18.0M | 28.6M | |
| Total Liab | 30.2M | 18.8M | 14.6M | 50.1M | 38.1M | 45.0M | |
| Other Current Liab | 9.1M | 9.2M | 236.0K | 9.5M | 14.3M | 7.4M | |
| Total Current Liabilities | 28.9M | 17.8M | 14.2M | 16.8M | 20.0M | 20.9M | |
| Property Plant And Equipment Net | 2.2M | 2.3M | 3.7M | 70K | 25.3M | 26.5M | |
| Accounts Payable | 4.3M | 5.9M | 6.4M | 122K | 355K | 337.3K | |
| Cash | 15.4M | 30.4M | 44.3M | 21.7M | 33.5M | 40.2M | |
| Non Current Assets Total | 2.5M | 5.3M | 4.2M | 238K | 59.3M | 62.3M | |
| Cash And Short Term Investments | 76.9M | 79.4M | 46.9M | 21.7M | 33.5M | 31.8M | |
| Other Current Assets | 4.2M | 6.8M | 2.8M | 2.7M | 2.6M | 2.5M | |
| Total Current Assets | 96.1M | 89.5M | 51.5M | 28.2M | 57.2M | 88.0M | |
| Accumulated Other Comprehensive Income | 34K | 5K | 40.2M | 2.3M | 1.5M | 1.5M | |
| Short Term Investments | 61.5M | 49.0M | 2.5M | 10.6M | 9.5M | 9.1M | |
| Non Currrent Assets Other | 257K | 528K | 472K | (11.6M) | 4.2M | 4.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.04) | Revenue Per Share 1.464 | Quarterly Revenue Growth (0.14) | Return On Assets 0.1018 |
The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.